Fundsmith Llp buys $509,054,342 stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : Fundsmith Llp scooped up 300,555 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 2,498,181 shares of C R Bard Inc which is valued at $509,054,342.C R Bard Inc makes up approximately 7.39% of Fundsmith Llp’s portfolio.

Other Hedge Funds, Including , Cramer Rosenthal Mcglynn reduced its stake in BCR by selling 22,780 shares or 8.72% in the most recent quarter. The Hedge Fund company now holds 238,500 shares of BCR which is valued at $48,599,145. C R Bard Inc makes up approx 0.74% of Cramer Rosenthal Mcglynn’s portfolio.Schroder Investment Management Group boosted its stake in BCR in the latest quarter, The investment management firm added 78,380 additional shares and now holds a total of 106,657 shares of C R Bard Inc which is valued at $23,352,550. C R Bard Inc makes up approx 0.04% of Schroder Investment Management Group’s portfolio.Mizuho Trust Banking Ltd. boosted its stake in BCR in the latest quarter, The investment management firm added 8,650 additional shares and now holds a total of 129,014 shares of C R Bard Inc which is valued at $27,787,035. C R Bard Inc makes up approx 0.08% of Mizuho Trust Banking Ltd.’s portfolio.Ami Asset Management Corp reduced its stake in BCR by selling 2,135 shares or 1.55% in the most recent quarter. The Hedge Fund company now holds 135,969 shares of BCR which is valued at $29,782,650. C R Bard Inc makes up approx 2.09% of Ami Asset Management Corp’s portfolio.

C R Bard Inc closed down -0.29 points or -0.13% at $215.73 with 3,46,269 shares getting traded on Monday. Post opening the session at $215.76, the shares hit an intraday low of $214.82 and an intraday high of $216.44 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, C R Bard Inc reported $2.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Oct 25, 2016. Analyst had a consensus of $2.55. The company had revenue of $941.90 million for the quarter, compared to analysts expectations of $931.71 million. The company’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.28 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. C R Bard Inc was Upgraded by Wells Fargo to ” Outperform” on Sep 16, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

C R Bard Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on C R Bard Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.